US Patent 7,081,251: Oxybutynin Transdermal Patch Claims, Expiration, Litigation Risk and Patent Landscape

US Patent 7,081,251 protects a transdermal oxybutynin treatment defined by three linked conditions: treatment of overactive bladder, a patch size of 13 to 39 cm², and an oxybutynin-to-N-desethyloxybutynin plasma AUC ratio of approximately 0.5:1 to 5:1. The patent covers both treatment methods and the corresponding patch article of manufacture.

The patent’s commercial relevance was concentrated in Oxytrol, a 3.9 mg/day oxybutynin transdermal system. Its practical exclusionary value has ended because the patent term expired in or around 2021, subject to the official patent-term calculation. It does not create a current barrier to an FDA-approved generic oxybutynin patch.

What does US Patent 7,081,251 protect?

The patent claims a pharmacokinetic approach to reducing oxybutynin-related anticholinergic adverse effects, particularly those associated with oral administration. Its principal limitation is not simply the use of oxybutynin in a patch. The claimed invention requires a patch that produces a specified systemic exposure relationship between oxybutynin and an oxybutynin metabolite.

The independent claims are:

Claim	Claim category	Principal limitations
1	Method of treatment	Human with overactive bladder; oxybutynin patch; 13-39 cm²; oxybutynin/metabolite AUC ratio of about 0.5:1 to 5:1; minimized anticholinergic or antimuscarinic adverse experience
12	Article of manufacture	Oxybutynin patch, optionally with permeation enhancer; same patch size and AUC-ratio requirements; minimized adverse experience

The claims use “comprising,” which generally permits additional ingredients, layers, excipients, or manufacturing features unless those additions remove a required limitation. The permeation enhancer is expressly optional and therefore is not required for infringement.

Claim 1: treatment method

Claim 1 requires proof of each of the following:

A human subject has overactive bladder.
Oxybutynin is administered.
Administration occurs through a transdermal patch.
The patch has a surface area from 13 cm² through 39 cm².
The resulting plasma AUC ratio of oxybutynin to an oxybutynin metabolite is approximately 0.5:1 to 5:1.
The treatment minimizes an anticholinergic or antimuscarinic adverse drug experience.

A competitor using a patch outside the stated size range would avoid literal infringement of claim 1, even if its formulation and pharmacokinetic profile were otherwise similar. A 39 cm² patch falls within the claim. A 13 cm² patch also falls within the claim. The claim does not require a particular patch geometry, backing layer, adhesive, reservoir, matrix, release rate, dose, or brand.

Claim 12: article of manufacture

Claim 12 is directed to the patch itself but incorporates a performance limitation. The article must be capable of producing the specified AUC ratio when administered at the claimed size.

This creates a potentially important proof issue. A product manufacturer may argue that the article claim cannot be infringed based only on composition or dimensions if the accused patch does not produce the claimed pharmacokinetic result. The patent holder would generally need clinical, pharmacokinetic, or validated product-performance evidence connecting the accused patch to the AUC ratio.

How do the dependent claims narrow the patent scope?

Claims 2 through 11 narrow method claim 1. Claims 13 through 22 correspond substantially to those limitations for article claim 12.

Claims	Limitation
2, 13	AUC ratio of about 1:1 to 5:1
3, 14	AUC ratio of about 0.8:1 to 1.5:1
4, 15	Metabolite is N-desethyloxybutynin
5, 16	R-, S-, or combined N-desethyloxybutynin
6, 17	Oxybutynin is a racemic mixture of R- and S-oxybutynin
7, 18	Oxybutynin is R-oxybutynin
8, 19	Patch size is 13 cm²
9, 20	Patch size is 39 cm²
10, 21	Concurrent use of multiple patches
11, 22	Multiple 13 cm² patches

Claim 3 is narrower than claim 2 because the range of 0.8:1 to 1.5:1 falls within the broader 1:1 to 5:1 range only in part. Claim 3’s range includes ratios below 1:1 that do not fall within claim 2’s literal range. As drafted, that creates an internal dependency issue because claim 3 depends on claim 2 while reciting a partially different range. The issued patent remains presumed valid, but the dependency structure could create claim-construction and validity disputes.

What pharmacokinetic relationship does the patent require?

The patent focuses on the ratio of exposure to parent oxybutynin versus exposure to N-desethyloxybutynin. Oral oxybutynin undergoes substantial first-pass metabolism, producing comparatively high metabolite exposure. Transdermal delivery reduces gastrointestinal and hepatic first-pass metabolism and can produce a higher relative exposure to oxybutynin.

The relevant metric is:

[ \text{AUC ratio} = \frac{\text{plasma AUC of oxybutynin}}{\text{plasma AUC of oxybutynin metabolite}} ]

Claim 1 covers a ratio of approximately 0.5:1 to 5:1. The narrower dependent claims focus on ratios between approximately 1:1 and 5:1, and 0.8:1 and 1.5:1.

The metabolite limitations are significant because the claims do not require only “an oxybutynin metabolite” in the commercial or scientific sense. Claims 4 and 5 specifically identify N-desethyloxybutynin, including its R and S forms. A generic developer could challenge whether its clinical or pharmacokinetic data establish the claimed ratio for the same metabolite, under the same sampling protocol, population, dose, and patch conditions.

What patch sizes are covered by US Patent 7,081,251?

The broad size limitation is 13 to 39 cm². The endpoints are expressly claimed in dependent claims 8, 9, 19 and 20.

Patch size	Status under the claims
12 cm²	Outside the express size range
13 cm²	Specifically claimed
20 cm²	Within the independent claims
25 cm²	Within the independent claims
39 cm²	Specifically claimed
40 cm²	Outside the express size range

The claims also cover concurrent administration of multiple patches. A regimen using three 13 cm² patches could fall within claims 10, 11, 21 and 22, assuming the AUC-ratio and other requirements are satisfied.

The size limitation is not equivalent to dose. A 13 cm² patch and a 39 cm² patch may use different drug loads, flux rates, adhesive systems, or application schedules. Infringement analysis therefore requires separate evaluation of surface area, oxybutynin delivery rate, formulation, and measured pharmacokinetics.

What formulations are protected by the patent?

The patent does not limit the independent claims to a specific formulation architecture. It can cover a patch containing oxybutynin in a matrix, reservoir, adhesive, or other transdermal configuration if the accused product satisfies the size and AUC-ratio limitations.

The patent expressly allows a permeation enhancer but does not require one. Potential formulation variables include:

Oxybutynin base or a pharmaceutically acceptable salt;
Racemic oxybutynin or R-oxybutynin;
Adhesive-based matrix systems;
Reservoir systems;
Polymer membranes;
Skin permeation enhancers;
Rate-controlling layers;
Occlusive backings;
Pressure-sensitive adhesives.

The dependent claims specifically reach racemic oxybutynin and R-oxybutynin. They also identify R- and S-N-desethyloxybutynin. The claims therefore extend beyond a single stereochemical form, although they do not automatically cover every oxybutynin formulation that lacks the claimed pharmacokinetic ratio.

What is the FDA and Orange Book status of the patent?

Oxytrol is an oxybutynin transdermal system associated with FDA NDA 021449. The product was approved as a prescription transdermal system and later became the first FDA-approved over-the-counter treatment for overactive bladder in the United States. FDA labeling identifies oxybutynin transdermal delivery as a treatment for urge urinary incontinence, urgency and frequency associated with overactive bladder. [2]

US Patent 7,081,251 was historically associated with the Oxytrol patent estate and was listed in the FDA Orange Book during the period when the patent had potential regulatory relevance. Orange Book listings do not extend patent life. They identify patents submitted by an NDA holder and can trigger the Hatch-Waxman certification and litigation framework while the patent remains in force. [3]

Because the patent has expired, it no longer supports a current 30-month stay based on a new Paragraph IV certification. It also does not provide a current basis for blocking FDA approval of an ANDA.

When did US Patent 7,081,251 lose exclusivity?

The patent issued on July 25, 2006. Its ordinary patent term was calculated from the applicable nonprovisional filing date, with any adjustment determined by the USPTO. Public patent records place the effective expiration in the 2021 period. The patent is therefore expired as of 2026 and cannot support a present-day injunction against a generic oxybutynin patch.

Event	Date or period
Patent issuance	July 25, 2006
Ordinary term basis	20 years from applicable nonprovisional filing date
Expected statutory expiration	2021 period
Current status	Expired
Current Paragraph IV blocking effect	None
Current biosimilar relevance	None

Patent expiry does not erase historical litigation exposure, damages claims accruing before expiration, or the validity of settlements entered while the patent was enforceable.

Which companies challenged or competed with Oxytrol?

The relevant competitive group consisted of:

Watson Pharmaceuticals, later part of Actavis and Allergan;
Noven Pharmaceuticals, which had transdermal drug-delivery expertise and commercial relationships in the patch sector;
Generic manufacturers seeking approval for oxybutynin transdermal systems;
OTC and prescription competitors such as tolterodine, solifenacin, darifenacin, fesoterodine and trospium.

Generic oxybutynin patch products could pursue an ANDA with a Paragraph IV certification against any unexpired Orange Book-listed patent. Once the relevant Oxytrol patents expired, the principal barriers shifted from patent exclusion to FDA product development, bioequivalence, manufacturing validation, supply reliability and commercial economics.

What Paragraph IV risks did the patent create?

During its enforceable period, a generic applicant would have had four principal options:

Certify that no relevant patent was listed.
Submit a Paragraph III certification and wait for patent expiration.
Submit a Paragraph IV certification asserting that the patent was invalid, unenforceable or not infringed.
File a section viii statement carving out a patented method of use, where the FDA-approved labeling permitted such a carve-out.

For this patent, a Paragraph IV case would likely focus on:

Whether the generic patch had a surface area of 13 to 39 cm²;
Whether the product produced the claimed AUC ratio;
Whether the claims were anticipated or obvious over earlier oxybutynin transdermal systems;
Whether “minimizing” an adverse experience was sufficiently definite;
Whether the article claims were improperly dependent on a clinical administration result;
Whether the claimed AUC ratio was inherent in prior-art patches;
Whether the patent specification adequately supported the full claimed range.

A generic product could attempt design-around strategies using a patch smaller than 13 cm² or larger than 39 cm². That approach would not eliminate every risk because other Oxytrol-related patents, regulatory exclusivities, trade secrets or non-patent manufacturing rights might remain relevant.

How strong is the patent estate for oxybutynin transdermal systems?

US Patent 7,081,251 was commercially meaningful but technically narrow. Its strength depended on the combination of patch size and pharmacokinetic outcome rather than on a broad composition claim.

Strength factor	Assessment
Coverage of transdermal oxybutynin generally	Limited
Coverage of 13-39 cm² patches	Strong within the literal range
Coverage of 39 cm² commercial-style patches	Strong if the AUC ratio is demonstrated
Dependence on clinical or PK evidence	High
Permeation-enhancer protection	No, enhancer is optional
Stereochemical coverage	Expressly reaches racemate and R-oxybutynin in dependent claims
Current enforcement value	None after expiration
Biosimilar protection	Not applicable
Manufacturing barrier	Limited unless process claims in related patents apply

The patent’s principal vulnerability was the AUC limitation. A patent owner would need to establish that the accused product produces the claimed ratio. A generic manufacturer could argue that the ratio varies with dose, patient characteristics, sampling times, analytical method, metabolite stereochemistry, patch placement and treatment duration.

What patent litigation and settlement issues affected Oxytrol?

The relevant Hatch-Waxman disputes would have involved the Orange Book-listed Oxytrol estate and ANDA applicants for oxybutynin transdermal systems. The likely litigation issues were claim construction, obviousness, anticipation, infringement of the patch-size limitation and whether pharmacokinetic results were inherent in the accused product.

A settlement involving an ANDA filer could have included:

A licensed entry date before patent expiration;
A launch date tied to patent invalidation or appellate outcome;
A supply or manufacturing arrangement;
A covenant not to sue;
Restrictions on labeling or product configuration.

The patent itself does not establish the terms of any commercial license or settlement. Patent assignment data identify ownership and recorded interests, but they do not necessarily disclose private licensing economics. [1]

How does US Patent 7,081,251 compare with competing oxybutynin patent strategies?

Strategy	Typical protection	Relationship to US 7,081,251
Broad transdermal composition	Patch containing oxybutynin	Broader in formulation, but may expire earlier
Patch geometry and dose	Defined size, drug load or delivery rate	Overlaps with the 13-39 cm² limitation
Pharmacokinetic profile	Parent-drug/metabolite exposure relationship	Central to US 7,081,251
Method of treating overactive bladder	Patient and therapeutic use	Claim 1 directly uses this approach
Stereochemical formulation	R-oxybutynin or defined enantiomeric ratio	Addressed in claims 6 and 7
Manufacturing process	Coating, lamination, drying and packaging	Not the focus of the supplied claims
Device or adhesive system	Patch construction and adhesion	Potentially covered by related patents, not these claims alone

The patent was best understood as a pharmacokinetic and therapeutic-use patent layered onto a transdermal delivery platform. It did not independently protect every oxybutynin patch.

What generic launch risks exist after patent expiration?

Current generic-entry risk is primarily regulatory and commercial rather than patent-based.

A generic manufacturer must address:

ANDA approval and product-specific bioequivalence requirements;
Adhesion and wear performance;
Drug content uniformity;
Residual solvent and extractables controls;
Stability over the labeled shelf life;
Manufacturing scale-up;
Skin irritation and sensitization;
Commercial reimbursement and pharmacy substitution;
Supply of transdermal adhesive and backing components.

Biosimilar risk is irrelevant because oxybutynin is a small-molecule drug. The appropriate pathway is an ANDA, not a biosimilar application under the Public Health Service Act.

Key Takeaways

US Patent 7,081,251 claims oxybutynin treatment through a 13-39 cm² transdermal patch.
The core technical limitation is an oxybutynin-to-metabolite plasma AUC ratio of about 0.5:1 to 5:1.
N-desethyloxybutynin is expressly identified in dependent claims.
The patent covers racemic oxybutynin and R-oxybutynin through dependent claims.
Permeation enhancer use is optional, not mandatory.
Claims 1 and 12 are the principal method and article claims.
Multiple-patch regimens, including multiple 13 cm² patches, are expressly addressed.
The patent was historically relevant to the Oxytrol Orange Book estate.
Its term expired in the 2021 period and it has no current Paragraph IV blocking effect.
Current competition is governed by FDA approval, manufacturing capability, supply and pricing rather than this patent.

FAQs about US Patent 7,081,251 and oxybutynin patches

Does a 39 cm² oxybutynin patch automatically infringe US Patent 7,081,251?

No. The patch must also satisfy the oxybutynin-to-metabolite AUC limitation and the applicable treatment or article-of-manufacture requirements.

Does the patent cover oral oxybutynin?

No. The independent claims require transdermal administration through a patch. Oral oxybutynin is outside the supplied claim scope.

Can a patch outside 13-39 cm² avoid the patent?

It may avoid literal infringement of the express size limitation, but related patents, equivalents arguments and other regulatory or contractual rights must be evaluated separately.

Is R-oxybutynin separately protected?

Yes. Claims 7 and 18 expressly recite R-oxybutynin. The independent claims, however, are not limited to the R enantiomer.

Does the expired patent still block an OTC oxybutynin product?

No. An expired patent cannot support a current injunction or Hatch-Waxman stay. FDA requirements, labeling, manufacturing and other live intellectual-property rights may still affect market entry.

References

United States Patent and Trademark Office. (2006). US Patent No. 7,081,251, method and composition for treating overactive bladder.
U.S. Food and Drug Administration. (2013). FDA approves first over-the-counter treatment for overactive bladder.
U.S. Food and Drug Administration. (2026). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (n.d.). Oxytrol (oxybutynin transdermal system) prescribing information.
United States Code, 35 U.S.C. § 154. (2024). Patent term and patent-term adjustment provisions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	488233	⤷ Start Trial
Australia	2001253782	⤷ Start Trial
Australia	2003287377	⤷ Start Trial
Australia	2003294239	⤷ Start Trial
Australia	2010200418	⤷ Start Trial
Australia	2012216593	⤷ Start Trial
Australia	5378201	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,081,251

Summary for Patent: 7,081,251